PolyPid Ltd. (PYPD)
NASDAQ: PYPD · Real-Time Price · USD
4.760
+0.030 (0.63%)
At close: May 19, 2026, 4:00 PM EDT
4.770
+0.010 (0.21%)
After-hours: May 19, 2026, 7:42 PM EDT
PolyPid Employees
As of December 31, 2025, PolyPid had 75 total employees, including 69 full-time and 6 part-time employees. The number of employees increased by 14 or 22.95% compared to the previous year.
Employees
75
Change (1Y)
14
Growth (1Y)
22.95%
Revenue / Employee
n/a
Profits / Employee
-$448,387
Market Cap
90.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 75 | 14 | 22.95% | 69 | 6 |
| Dec 31, 2024 | 61 | -1 | -1.61% | 57 | 4 |
| Dec 31, 2023 | 62 | 2 | 3.33% | 59 | 3 |
| Dec 31, 2022 | 60 | -19 | -24.05% | 57 | 3 |
| Dec 31, 2021 | 79 | 10 | 14.49% | 75 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Seer, Inc. | 124 |
| Pelthos Therapeutics | 92 |
| ImmuCell | 73 |
| Biomea Fusion | 41 |
| Aardvark Therapeutics | 40 |
| Oncolytics Biotech | 29 |
| NeurAxis | 24 |
| LeonaBio | 19 |
PYPD News
- 6 days ago - PolyPid reports Q1 EPS (35c), consensus (43c) - TheFly
- 6 days ago - PolyPid Earnings Call Transcript: Q1 2026 - Transcripts
- 6 days ago - PolyPid Earnings release: Q1 2026 - Filings
- 6 days ago - PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 13 days ago - PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026 - GlobeNewsWire
- 21 days ago - PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting - GlobeNewsWire
- 5 weeks ago - PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026 - GlobeNewsWire
- 7 weeks ago - PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA - GlobeNewsWire